Vivasure Medical has received CE mark approval for its PerQseal Elite vascular closure system, providing a new bioresorbable ...

Novocure has obtained CE Mark approval for its Optune Lua device to treat adults with metastatic non-small cell lung cancer ...

(RTTNews) - Roche (RHHBY) announced that it received CE Mark for its Chest Pain Triage algorithm. The algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome or ACS in ...

Vivasure Medical announced today that it received CE mark approval for its PerQseal Elite vascular closure system.

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

Novocure (NVCR) announced that Optune Lua has received a CE Mark for the treatment of adult patients with metastatic non-small cell lung cancer ...

“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s efforts to improve outcomes for people living with aggressive cancers ...

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt PFA System The 12-month results of the Volt ...

Vivasure Medical has received CE mark approval for its PerQseal Elite vascular closure system, providing a new bioresorbable option for percutaneous vessel closure. Vivasure’s device is designed ...

Vivasure Medical, an Ireland-based developer of fully absorbable technology for percutaneous vessel closure, announced ...